| Standard FDA Review for Pfizer Drug - Zacks.com |
|
|
Zacks.com The company is seeking approval for the treatment of patients with advanced renal cell carcinoma (RCC). The regulatory application was based on data from the phase III AXIS 1032 study which compared axitinib with Onyx Pharmaceuticals/Bayer's (ONXX ... US FDA accepts Pfizer's filing for standard review of axitinib for patients |